Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments

European Journal of Ophthalmology

Volumn 14, Issue 5, 2004, Pages 407-415

  Haverkamp, F ^a   Wuensch, S ^b   Fuchs, M ^b   Stewart, William C ^c,d  

^a UNIVERSITY OF BONN   (Germany)

^b Geilenkirchen D   (Germany)

^c University of South Carolina   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Quality; Safety

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST; MIOTIC AGENT; PILOCARPINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHEMOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; EYE BURNING; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; FATIGUE; FEMALE; FOREIGN BODY; GLAUCOMA; HEADACHE; HUMAN; IMPOTENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PERIOCULAR EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TASTE DISORDER; UVEITIS; VISUAL DISORDER; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 8344219721     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210401400508     Document Type: Article

References (20)

1. Book SA. Essentials of statistics. In: Arthur AA, Rogers J, and Bradley JW, eds. Testing statistical hypotheses. New York: McGraw-Hill Book Company, 1978; 117-22.
2. Siegel S. Non parametric statistics. Series in psychology. New York: McGraw-Hill Book Company, 1956; 63-7.
3. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995; 102: 1743-52.
4. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-47.
5. Watson P, Stjernschantz J. A six-month, randomised, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37.
6. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631-5.
7. Susanna R Jr, Giampani J Jr, Borges AS, Vessani RM, Jordao MI. A double-masked, randomised clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001; 108: 259-63.
8. Fechtner R, Clineschmidt C, Getson A, Adamson I. A three month, parallel, randomised, observer-masked, multicenter study comparing Cosopt to Xalatan in patients with elevated IOP. Invest Ophthalmol Vis Sci 1999; 40 (Suppl): S665.
9. Konstas AGP, Holmes KT, Stewart WC. A comparison of the efficacy and safety of latanoprost 0.005% every evening versus timolol/dorzolamide fixed combination twice daily. Invest Ophthalmol Vis Sci 2001; 42 (Suppl): S420.
10. Dubiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2002; 45 (Suppl): S353-60.
11. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-84.
12. Schumer R, Camras C, Madahl A. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47 (Suppl): S219.
13. Stewart WC. How the new prostaglandins stack up: A look at what clinical studies reveal about travoprost and bimatoprost in relation to latanoprost. Rev Ophthalmol 2002; 9: 117-20.
14. Diestelhorst M, Nordmann JP, Toris CB. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. Surv Ophthalmol 2002; 47 (Suppl): S155-61.
15. Clifford TB, Smith SL, Sine CS, Pruitt CA, Hudgins AC, Stewart WC. The use of latanoprost 0.05% once daily to reduce the intraocular pressure in patients with uveitis. Invest Ophthalmol Vis Sci 1998; 38 (Suppl): S256.
16. Stewart WC, Day DG, Stewart JA, et al. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocular Pharmacol Ther 2000; 16: 557-64.
17. Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL. Efficacy of carteolol 1% versus timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol 1997; 124: 498-505.
18. Javitt JC, Schiffmanm RM. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomised clinical trial. Brimonidine Outcomes Study Group 1. J Glaucoma 2000; 9: 224-34.
19. Javitt JC, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma 2000; 9: 398-408.
20. Janz NK, Wren PA, Lichter PR, et al. Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001; 108: 1954-65.